Artal Group S.A. Has $2.13 Million Position in Aduro Biotech, Inc. (ADRO)

Artal Group S.A. increased its position in shares of Aduro Biotech, Inc. (NASDAQ:ADRO) by 100.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 200,000 shares of the biotechnology company’s stock after buying an additional 100,000 shares during the period. Artal Group S.A. owned 0.26% of Aduro Biotech worth $2,130,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ADRO. Bank of New York Mellon Corp raised its stake in Aduro Biotech by 3.8% during the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after buying an additional 5,470 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in Aduro Biotech by 15.9% during the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after buying an additional 2,119 shares during the last quarter. American International Group Inc. raised its stake in Aduro Biotech by 7.1% during the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after buying an additional 1,447 shares during the last quarter. Vanguard Group Inc. raised its stake in Aduro Biotech by 2.1% during the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock worth $25,617,000 after buying an additional 48,840 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Aduro Biotech by 6.0% during the first quarter. Geode Capital Management LLC now owns 262,809 shares of the biotechnology company’s stock worth $2,825,000 after buying an additional 14,946 shares during the last quarter. 43.10% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Artal Group S.A. Has $2.13 Million Position in Aduro Biotech, Inc. (ADRO)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/11/20/artal-group-s-a-has-2-13-million-position-in-aduro-biotech-inc-adro.html.

Aduro Biotech, Inc. (NASDAQ ADRO) traded down $0.20 on Monday, reaching $8.80. 373,900 shares of the company’s stock traded hands, compared to its average volume of 406,264. Aduro Biotech, Inc. has a 12-month low of $6.01 and a 12-month high of $14.85.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The company had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. During the same period last year, the firm posted ($0.54) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. equities research analysts predict that Aduro Biotech, Inc. will post -1.28 EPS for the current year.

ADRO has been the subject of a number of analyst reports. BidaskClub raised shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Aduro Biotech in a research note on Wednesday, September 27th. Oppenheimer Holdings, Inc. initiated coverage on shares of Aduro Biotech in a research note on Monday, October 30th. They set a “buy” rating and a $15.00 target price for the company. Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.14.

In other news, CEO Stephen T. Isaacs sold 40,000 shares of Aduro Biotech stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $10.78, for a total transaction of $431,200.00. Following the completion of the transaction, the chief executive officer now directly owns 213,921 shares in the company, valued at $2,306,068.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen T. Isaacs sold 16,400 shares of Aduro Biotech stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $7.96, for a total transaction of $130,544.00. Following the transaction, the chief executive officer now owns 190,321 shares of the company’s stock, valued at $1,514,955.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 224,480 shares of company stock valued at $2,194,001. Insiders own 6.60% of the company’s stock.

Aduro Biotech Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

What are top analysts saying about Aduro Biotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aduro Biotech Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit